GLP1R and breast carcinoma: They discovered that the GLP‐1R antagonist exendin completely reversed the antiproliferative effect of exendin‐4 and that GLP‐1R knockdown eliminated the reduction in MCF‐7 cell numbers by exendin‐4, suggesting that exendin‐4 reduces breast cancer cell numbers through GLP‐1R activation.